Featured
GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
Read
News & Presentations
Financial & Stock Information
Corporate Governance
Investor Resources
info@ghres.com
investors@ghres.com
clinicaltrials@ghres.com
careers@ghres.com